281 related articles for article (PubMed ID: 12091119)
21. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
22. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Krejci M; Doubek M; Brychtova Y; Stehlikova O; Chovancova J; Tichy B; Francova HS; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
Ann Hematol; 2013 Jan; 92(2):249-54. PubMed ID: 23014659
[TBL] [Abstract][Full Text] [Related]
24. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
25. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
26. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
27. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
30. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
33. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
34. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
35. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
37. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
38. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]